Headline USA – Florida Gov. Ron DeSantis ripped the Biden administration for cancelling emergency-use authorization for Regeneron and Eli Lilly’s monoclonal antibody therapies, according to a press release.
“Without a shred of clinical data to support this action, Biden has forced trained medical professionals to choose between treating their patients or breaking the law,” he said.
The Food and Drug Administration revoked the authorization on Jan. 23 and announced that states would stop receiving shipments.
“This indefensible edict takes treatment out of the hands of medical professionals and will cost some Americans their lives,” DeSantis said. “There are real-world implications to Biden’s medical authoritarianism – Americans’ access to treatments is now subject to the whims of a failing president.”
Officials said they blocked the highly effective antibody treatments because they do not work against the Omicron COVID-19 variant.
Political commentator Benny Johnson said corporate interests have captured the FDA and other federal health agencies and tailored their policies to ensure maximum profit from their untested injections.
Less than a month ago, DeSantis accused the Biden admininstration of creating an “artificial shortage” of antibody treatments and begged federal officials to send Florida more shipments.
Surgeon General Dr. Joseph Ladapo said doctors need every treatment option available.
“In our field of medicine, when someone comes to you seeking a treatment that could save their life, it is essential to have treatment options to ensure health care providers can make the best decisions for their patients,” he said.
DeSantis has emphasized monoclonal antibody treatments more than COVID-19 shots in the past few months, but he has still encouraged the state’s citizens to get the shot if they desire it.
Copyright 2022. No part of this site may be reproduced in whole or in part in any manner without the permission of the copyright owner. To inquire about licensing content, use the contact form at https://headlineusa.com/advertising.